France pain management drugs market is anticipated to grow at a CAGR of 2.11% from 2025 to 2030.
The demand for pain management drugs in France is being driven by the rising prevalence of chronic diseases, growing cases of cancer, chronic back pain, and arthritis among others. The well-developed healthcare sector is also one of the major factors that augment the demand for pain management drugs in the country. This is bringing in significant support from the government in this country.
Likewise, the majority of total health expenditure is funded by the government on account of growing concerns regarding the burden of rising out-of-pocket expenditure, particularly among people without any good complementary health insurance. This is increasing the adoption of advanced healthcare services among people which also includes treatment of major chronic diseases and costly surgical procedures as well, which is anticipated to drive the demand for pain management drugs in the country, thereby boosting the market growth. Hence, initiatives such as Complementary Health Insurance (CHI) offered by the French government also financial protection for the population.
The growing strength of the old-age population has further escalated the prevalence of body-pain-related issues such as chronic back pain and rheumatoid arthritis in France. According to the European Commission, the total population of France is set to grow from 68.05 million in 2022 to 69.453 million by 2030 and 70.623 million by 2050. Hence, during such a time frame the old-age dependency ratio of the population aged 65 years and above is expected to increase from 38.2% in 2020 to 53.2% by 2050.
Likewise, according to the “Health at Glance 2024 Europe” issued by the European Commission, more than 40% of the French population aged 65 years and above suffers from at least chronic disease which further increases their scale of physical inactivity due to high levels of body pain. Additionally, the ongoing investment in bolstering pharmaceutical production and improving the frequency of over-the-counter medicines for generic purposes has established a new framework for pain management drug sales in the French market. Hence major market players namely Novartis Pharmaceutical Corporation, Pfizer Inc, GlaxoSmithKline Plc, and Sanofi S.A. offer an extensive portfolio to meet the consumer requirement for varied body pain acting as an additional driving factor for market growth at the country level.
France Pain Management Drug Market Segmentation